Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S.; Köller, M.; S. Black, R.; Jenkins, Lisa; G. Griffith, Sue; C. Fox, Nick; S. Eisner, Larry; Kirby, L.; Boada Rovira, M.; Forette, F.; Orgogozo, Jean‐Marc

doi:10.1212/01.wnl.0000159740.16984.3c

Public

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Published in Neurology • May 10, 2005

Authors:

S. Gilman

M. Köller

R. S. Black

Abstract

BACKGROUND: AN1792 (beta-amyloid [Abeta]1-42) immunization reduces Abeta plaque burden and preserves cognitive function in APP transgenic mice. The authors report the results of a phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interru...

Subject

Medicine

Internal medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!